<DOC>
	<DOCNO>NCT00529503</DOCNO>
	<brief_summary>This randomized trial estimate activity R-ICE plus SGN-40 vs. R-ICE plus placebo patient DLBCL . The study assess safety tolerability measure additional clinical benefit observe patient receive SGN-40 .</brief_summary>
	<brief_title>A Randomized Phase IIb Placebo-Controlled Study R-ICE Chemotherapy With Without SGN-40 Patients With DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Confirmed diagnosis de novo transform DLBCL , follicular grade 3b lymphoma . Received least four cycle firstline therapy RCHOP , equivalent . Best clinical response firstline therapy stable disease , partial response , complete response . At least one measureable lesion great equal 1.5cm radiographic image positive FDGPET scan . Leptomeningeal central nervous system lymphoma . Received therapy relapse progressive disease except local radiation , steroid , rituximab . Received hematopoietic stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Antigens , CD40</keyword>
	<keyword>Antibody , Monoclonal</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
</DOC>